The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

This funding, announced Friday by Moderna, builds on the $176 million it received from HHS last year to support earlier stages of vaccine research.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Moderna (MRNA – Research Report), with a price target ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top ...

Brooklyn Investment Group reduced its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 34.8% during the 4th quarter, ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.